This project characterizes osteosarcomas by theirs response to growth factors and defines early events regulated by growth factors in osteosarcoma cells. Many osteosarcoma cell lines produce PDGF, a potent mitogen. Antisera to PDGF and to PDGF receptors will be used to define tumors which produce PDGF and may have the capacity to respond to it. Production of PDGF by tumor cells in vivo may affect prognosis. PDGF production either directly stimulates growth of the tumor cells (autocrine) or growth of surrounding stromal cells (paracrine). To differentiate between these two mechanisms, production of endogenous PDGF will be inhibited by use of either antisense oligonucleotides or conditionally active antisense constructs. An autocrine mechanism of stimulation would be suggested if: 1. growth is restricted by inhibition of endogenous PDGF synthesis; and 2. addition of exogenous PDGF to cells with inhibited endogenous PDGF production restores growth. Osteosarcomas which do not produce PDGF will also be investigated. One, the MG-63 cell line, does not grow in response to PDGF but does express c- myc RNA. Unlike other cell lines, however, PDGF stimulates c-myc expression in a protein kinase C- independent fashion. It will be learned if: 1. resistance to PDGF-induced growth and protein kinase C-independent c-myc expression is a general property of non-PDGF-producing osteogenic sarcoma cells; and 2. exogenous PDGF stimulates protein kinase C- independent c-myc expression by PDGF producing osteosarcoma cells when endogenous PDGF synthesis is inhibited. Because PDGF stimulates c-myc RNA expression independently of protein kinase C in MG-63 cells, there is likely to be a defect in phosphoinositide metabolism. To characterize this defect PDGF stimulated production of inositol phosphates and diacylglycerol will be characterized as will complex formation between the activated PDGF- receptors and phospholipase C-gamma. Growth factor regulated early gene expression will be examined in MG-63 cells. Particular attention will be paid to IGF-1 because IGF-1 stimulates growth of these cells. A cDNA library will be prepared from IGF-1 treated cells to identify and characterize IGF-1 regulated genes that potentially control growth. In summary, this project characterizes osteogenic tumor cells by their response to growth factors and defines early events regulated by growth factors in these cells.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA047983-04
Application #
3807955
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
4
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Children's Hospital of Philadelphia
Department
Type
DUNS #
073757627
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Moshier, J A; Skunca, M; Wu, W et al. (1996) Regulation of ornithine decarboxylase gene expression by the Wilms' tumor suppressor WT1. Nucleic Acids Res 24:1149-57
Fredericks, W J; Galili, N; Mukhopadhyay, S et al. (1995) The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3. Mol Cell Biol 15:1522-35
Amin, K M; Litzky, L A; Smythe, W R et al. (1995) Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma. Am J Pathol 146:344-56
Werner, H; Shen-Orr, Z; Rauscher 3rd, F J et al. (1995) Inhibition of cellular proliferation by the Wilms' tumor suppressor WT1 is associated with suppression of insulin-like growth factor I receptor gene expression. Mol Cell Biol 15:3516-22
Hol, F A; Hamel, B C; Geurds, M P et al. (1995) A frameshift mutation in the gene for PAX3 in a girl with spina bifida and mild signs of Waardenburg syndrome. J Med Genet 32:52-6
Macina, R A; Barr, F G; Galili, N et al. (1995) Genomic organization of the human PAX3 gene: DNA sequence analysis of the region disrupted in alveolar rhabdomyosarcoma. Genomics 26:1-8
Ryan, G; Steele-Perkins, V; Morris, J F et al. (1995) Repression of Pax-2 by WT1 during normal kidney development. Development 121:867-75
Morris, J F; Rauscher 3rd, F J; Davis, B et al. (1995) The myeloid zinc finger gene, MZF-1, regulates the CD34 promoter in vitro. Blood 86:3640-7
Barr, F G; Chatten, J; D'Cruz, C M et al. (1995) Molecular assays for chromosomal translocations in the diagnosis of pediatric soft tissue sarcomas. JAMA 273:553-7
Bennicelli, J L; Fredericks, W J; Wilson, R B et al. (1995) Wild type PAX3 protein and the PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma contain potent, structurally distinct transcriptional activation domains. Oncogene 11:119-30

Showing the most recent 10 out of 75 publications